M3 Europe and SEC Pharma are mergingMarch 9, 2012
Two of Europe’s leading pharmaceutical recruitment suppliers are uniting to become one of the largest specialist companies in the sector.
Previously both companies, owned by RDL Corporation, operated independently but as from 12th March 2012, M3 Europe and SEC Pharma will be united under the SEC Pharma brand and under one management team.
The merger will improve the level of service to customers (clients, contractors and candidates), providing a larger, more comprehensive and more specialist service in all sectors of the European pharmaceutical recruitment market.
The combined team of forty recruitment consultants will be able to specialise even further in distinct vertical skill areas and geographic market sectors, providing a more expert, knowledgeable and dedicated service to customers. The team will also be able to flex better to the demands of larger clients, with the establishment of a business wide resource pool to recruit for large volume projects. SEC will retain the two main offices in London and Woking and all current client relationships will remain with existing recruitment consultant,
The merger will provide a stronger platform for SEC to invest in the pharmaceutical recruitment market, and the business has plans to double the size of its market share within five years.
Key facts on the new enlarged SEC Pharma include:
- A team of more than 40 consultants
- Over 100 active clients throughout Europe
- Dedicated focus on Clinical, Regulatory, Medical Affairs, Biometrics, Drug Safety, Marketing and many other pharmaceutical specialisms
- Two major offices in London and Woking
- Native consultants for France, Spain and Italy plus 12 European languages spoken fluently